Affective symptoms in multiple system atrophy and Parkinson's disease: response to levodopa therapy
- PMID: 10201434
- PMCID: PMC1736312
- DOI: 10.1136/jnnp.66.4.541
Affective symptoms in multiple system atrophy and Parkinson's disease: response to levodopa therapy
Abstract
The objective was to determine the extent to which psychiatric disturbances (especially mood disorders) generally considered poor prognostic factors, are present in patients with striatonigral (SND) type multiple system atrophy (MSA) compared with patients with idiopathic Parkinson's disease (IPD). The Hamilton depression scale (HAM-D), brief psychiatric rating scale (BPRS), and Unified Parkinson's disease rating scale (UPDRS) were administered to clinically probable non-demented patients with SND-type MSA and patients with IPD matched for age and motor disability, at baseline and after receiving levodopa. At baseline total HAM-D score was greater in patients with IPD. Overall, BPRS score did not differ between the two groups; however, patients with IPD scored higher on anxiety items of the BPRS, and patients with MSA had higher scores on the item indicating blunted affect. After levodopa, both groups improved significantly in UPDRS and HAM-D total scores (just significant for patients with MSA). Patients with IPD improved significantly in total BPRS score but patients with MSA did not. At baseline patients with IPD were more depressed and anxious than patients with MSA who, by contrast, showed blunted affect. After levodopa, depression and anxiety of patients with IPD improved significantly whereas the affective detachment of patients with MSA did not change. Major neuronal loss in the caudate and ventral striatum, which are part of the lateral orbitofrontal and limbic circuits, may be responsible for the blunted affect not responsive to levodopa therapy found in patients with MSA.
Similar articles
-
Serum prolactin levels in Parkinson's disease and multiple system atrophy.Clin Auton Res. 2002 Oct;12(5):393-8. doi: 10.1007/s10286-002-0025-y. Clin Auton Res. 2002. PMID: 12420085
-
Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease.Mov Disord. 2002 Jul;17(4):701-9. doi: 10.1002/mds.10171. Mov Disord. 2002. PMID: 12210859
-
Clinical characteristics and quality of life in Chinese patients with multiple system atrophy.Brain Behav. 2018 Dec;8(12):e01135. doi: 10.1002/brb3.1135. Epub 2018 Oct 30. Brain Behav. 2018. PMID: 30378279 Free PMC article.
-
Parkinsonism. Multiple system atrophy.Baillieres Clin Neurol. 1997 Apr;6(1):187-204. Baillieres Clin Neurol. 1997. PMID: 9426875 Review.
-
Does levodopa slow or hasten the rate of progression of Parkinson's disease?J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42. doi: 10.1007/s00415-005-4008-5. J Neurol. 2005. PMID: 16222436 Review.
Cited by
-
Depression in multiple system atrophy: Views on pathological, clinical and imaging aspects.Front Psychiatry. 2022 Sep 8;13:980371. doi: 10.3389/fpsyt.2022.980371. eCollection 2022. Front Psychiatry. 2022. PMID: 36159911 Free PMC article. Review.
-
Psychiatric symptoms in Parkinson's disease.Curr Neurol Neurosci Rep. 2002 Jul;2(4):303-9. doi: 10.1007/s11910-002-0005-6. Curr Neurol Neurosci Rep. 2002. PMID: 12044249 Review.
-
Multiple system atrophy: current and future approaches to management.Ther Adv Neurol Disord. 2010 Jul;3(4):249-63. doi: 10.1177/1756285610375328. Ther Adv Neurol Disord. 2010. PMID: 21179616 Free PMC article.
-
Pathomechanisms of neuropsychiatric disturbances in atypical parkinsonian disorders: a current view.J Neural Transm (Vienna). 2025 Apr;132(4):495-518. doi: 10.1007/s00702-025-02890-7. Epub 2025 Feb 15. J Neural Transm (Vienna). 2025. PMID: 39954076 Review.
-
Neuropsychiatric aspects of Parkinson's disease: recent advances.Curr Psychiatry Rep. 2003 May;5(1):68-76. doi: 10.1007/s11920-003-0012-6. Curr Psychiatry Rep. 2003. PMID: 12686005 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical